AHA: New emphasis on percent LDL reduction on-treatment
November 25, 2015|Cardiology News
Author and Disclosure Information
AT THE AHA SCIENTIFIC SESSIONS
It will be important for the ongoing randomized trials of PCSK9 inhibitors to report results stratified by the percent reduction in LDL cholesterol achieved by background statin therapy. This will be useful, as Dr. Ridker said, in figuring out how best to allocate this new class of lipid-lowering medications, added Dr. Pencina, professor of biostatistics and bioinformatics at Duke University, Durham, N.C.
Dr. Ridker reported receiving research grants from AstraZeneca, Pfizer, Amgen, and the National Institutes of Health.
